SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
The Neuroscientist
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Marek, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marek, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Other

Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging

Kenneth Marek

Department of Neurology Yale University School of Medicine New Haven, Connecticut

In recent decades, identification of the dopaminergic deficit in Parkinson's disease has spawned an explo sion of research in the molecular neurobiology of the basal ganglia. In vivo imaging has provided a tool to bridge developments in basic neuroscience and clinicial neurology. Imaging studies have opened a unique window on the neurochemical pathophysiology of Parkinson's disease and more specifically on the onset, progression and physiology of the degenerative process. As we are poised on the brink of new protective and restorative therapies for Parkinson's disease, the potential of imaging to teach us about in vivo brain neurochemistry offers both promise and challenge. NEUROSCIENTIST 5:333-340, 1999

Key Words: KEY WORDS Parkinson's disease • Basal ganglia • PET • SPECT • Dopamine transporter • FDOPA

The Neuroscientist, Vol. 5, No. 5, 333-340 (1999)
DOI: 10.1177/107385849900500519
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
K. Marek and D. Jennings
Can we image premotor Parkinson disease?
Neurology, February 17, 2009; 72(7_Supplement_2): S21 - S26.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
S. T. DeKosky and K. Marek
Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders
Science, October 31, 2003; 302(5646): 830 - 834.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Marek, D. Jennings, and J. Seibyl
Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa
Neurology, September 23, 2003; 61(90063): S43 - 48.
[Full Text]

Home page
 JAMAHome page
Parkinson Study Group
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
JAMA, October 18, 2000; 284(15): 1931 - 1938.
[Abstract] [Full Text] [PDF]


Advertisement